{"product_id":"zeria-bcg-matrix","title":"Zeria Pharmaceutical Co. Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZeria Pharmaceutical’s product portfolio shows a mix of resilient cash generators in established therapeutic areas and high-potential candidates in oncology and specialty care that could be Stars with the right investment; some legacy OTC lines behave like Dogs and may need pruning. This snapshot hints at strategic trade-offs between R\u0026amp;D allocation and market consolidation as regulatory headwinds reshape growth prospects. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsacol and Dificlir Overseas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAsacol and Dificlir sit in Zeria Pharmaceutical Co.’s BCG Matrix as stars: both drive 2025 international growth with Asacol (ulcerative colitis) and Dificlir (C. difficile) reporting combined overseas sales up 42% YoY to ¥28.6 billion in FY2024, lifting international revenue share to 38%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcofide for Functional Dyspepsia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcofide, Zeria Pharmaceutical Co’s first-in-class agent for functional dyspepsia, remains a Star—2024 sales ~¥4.2bn (JPY), growing ~12% YoY—driven by expansion in Asia (Malaysia, Vietnam launches 2023–2024) and trials for pediatric FD (Phase III start Q2 2025 planned). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeltassa for Hyperkalemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLaunched in Japan in early 2025, Veltassa (patiromer) addresses a large unmet need: Japan has an estimated 1.2 million patients with chronic kidney disease at risk of hyperkalemia, and initial hospital uptake hit 18% of target hospitals within six months.\u003c\/p\u003e\n\u003cp\u003eBacked by Phase III evidence and global real-world data showing a 60–70% sustained potassium control, Veltassa is rapidly gaining share in hospitals and specialty clinics, reaching ¥1.4 billion in sales in H1 2025.\u003c\/p\u003e\n\u003cp\u003eZeria is funding aggressive market penetration—field sales expansion, guideline engagement, and hospital contracts—allocating ~¥2.5 billion CAPEX in 2025 to make Veltassa a standard of care, mirroring overseas market conversion rates near 25% within two years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHepalyse W Range Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHepalyse W Range Expansion is a Star for Zeria Pharmaceutical Co. in consumer healthcare: Hepalyse W Shine, launched November 2024, helped push Hepalyse W category sales up ~28% in FY2024 to ¥12.4bn, driven by convenience-store distribution and the fatigue-countermeasure segment.\u003c\/p\u003e\n\u003cp\u003eHigh brand recognition and youth-focused ads raise trial and repeat purchase; Zeria spent ~¥1.8bn on marketing for Hepalyse W in 2024 (≈14% of category sales), supporting a rising market share now estimated at 16% in convenience channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch: Hepalyse W Shine, Nov 2024\u003c\/li\u003e\n\u003cli\u003eFY2024 category sales: ¥12.4bn (+28%)\u003c\/li\u003e\n\u003cli\u003eMarketing spend: ¥1.8bn (≈14% of sales)\u003c\/li\u003e\n\u003cli\u003eConvenience-store share: ~16%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZeria's Asian Market Export Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZeria Pharmaceutical’s Asian export unit, led by subsidiary F.T. Pharma in Vietnam, qualifies as a Star in the BCG matrix: operating in high-growth Southeast Asian markets where healthcare spending rose ~7% CAGR to 2024 and Zeria reports double-digit export revenue growth (about 18% YoY in 2024) while gaining share with ethical and OTC lines.\u003c\/p\u003e\n\u003cp\u003eThe unit is scaling rapidly, backed by heavy capex: Zeria disclosed JPY 12.5 billion (≈USD 85M) in 2024–25 for new plants and logistics to support regional leadership, improving capacity and reducing lead times for ASEAN distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth market: SE Asia healthcare spend +7% CAGR to 2024\u003c\/li\u003e\n\u003cli\u003eRevenue growth: export sales ~18% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eCapex: JPY 12.5B (~USD 85M) for new plants (2024–25)\u003c\/li\u003e\n\u003cli\u003eProduct mix: ethical + OTC scaling market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong FY24 export surge: Asacol+Dificlir +42% to ¥28.6bn; Hepalyse W +28%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Asacol + Dificlir drove FY2024 overseas sales +42% to ¥28.6bn (international share 38%); Acofide ¥4.2bn (+12% YoY) with Asia expansion; Veltassa launched H1 2025, ¥1.4bn H1 sales, 18% hospital uptake; Hepalyse W Shine pushed category to ¥12.4bn (+28%), convenience share ~16%; SE Asia exports +18% YoY, JPY12.5bn capex (2024–25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\/Unit\u003c\/th\u003e\n\u003cth\u003e2024\/ H1 2025\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsacol+Dificlir\u003c\/td\u003e\n\u003ctd\u003e¥28.6bn\u003c\/td\u003e\n\u003ctd\u003e+42% YoY\u003c\/td\u003e\n\u003ctd\u003eIntl share 38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcofide\u003c\/td\u003e\n\u003ctd\u003e¥4.2bn\u003c\/td\u003e\n\u003ctd\u003e+12% YoY\u003c\/td\u003e\n\u003ctd\u003eAsia launches, PhIII peds Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeltassa\u003c\/td\u003e\n\u003ctd\u003e¥1.4bn (H1 2025)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e18% hospital uptake; 60–70% control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepalyse W\u003c\/td\u003e\n\u003ctd\u003e¥12.4bn\u003c\/td\u003e\n\u003ctd\u003e+28% YoY\u003c\/td\u003e\n\u003ctd\u003eConvenience share ~16%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSE Asia exports\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e+18% YoY\u003c\/td\u003e\n\u003ctd\u003eCapex JPY12.5bn (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG review of Zeria: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest recommendations and trend impacts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix positioning Zeria’s units for quick C-suite decisions, export-ready and print-optimized for A4 or mobile PDFs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Hepalyse Pharmaceutical Range\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe traditional Hepalyse pharmaceutical range is Zeria Pharmaceutical Co.’s primary cash cow, holding roughly 45–50% share of Japan’s liver-tonic prescription market and generating an estimated JPY 18–22 billion in annual EBITDA (2024). \u003c\/p\u003e\n\u003cp\u003eIn a mature domestic market the line needs little new R\u0026amp;D, delivering steady high-margin free cash flow (approx. 25–30% margin), which funds Zeria’s aggressive R\u0026amp;D pipeline and planned international expansion through 2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChondroitin Range for Joint Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZeria Pharmaceutical Co.s Chondroitin range is a market leader in Japan for arthritis and lumbago, holding an estimated 28% share of OTC joint supplements in 2024 and generating roughly ¥6.5 billion in annual sales that year. The market is mature with annual growth near 1–2%, but Japan’s 28% population aged 65+ (2024) sustains steady demand. Low incremental marketing spend and high brand recognition keep gross margins around 45%, making the range a dependable cash cow in Zeria’s BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZinc-containing Anti-ulcerants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZinc-containing anti-ulcerants at Zeria Pharmaceutical Co. deliver steady revenue, generating about ¥4.2 billion JPY in 2024 (~US$30.5M), reflecting decades of high market penetration in Japan’s mature GI market (annual growth ~1–2%).\u003c\/p\u003e\n\u003cp\u003eClassified as BCG cash cows, these low-growth products show stable margins near 28% and are optimized for cost efficiency and steady cash flow.\u003c\/p\u003e\n\u003cp\u003eCash from these drugs funds R\u0026amp;D for next-gen GI therapies; FY2024 cash allocation to GI pipeline rose to 18% of operating cash, up from 12% in 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWithOne Botanical Laxatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWithOne Botanical Laxatives is a mature Zeria Pharmaceutical Co. brand commanding ~35% share of Japan’s OTC botanical laxative market (2024), delivering ~¥3.6bn revenue and ~¥900m operating cash flow in FY2024 with low single-digit volume variance year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe range needs mainly maintenance marketing—~¥120m ad spend in 2024—and supports corporate overheads while cushioning volatility in newer Rx and export units.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: 25% operating margin on ¥3.6bn yields ¥900m cash flow; ad spend \u0026lt;3.5% of sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share ~35% (Japan, 2024)\u003c\/li\u003e\n\u003cli\u003eRevenue ~¥3.6bn (FY2024)\u003c\/li\u003e\n\u003cli\u003eOperating cash flow ~¥900m (FY2024)\u003c\/li\u003e\n\u003cli\u003eAd spend ~¥120m (2024), ≈3.3% of sales\u003c\/li\u003e\n\u003cli\u003eStable volumes, low promotional needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIona Cosmetics and Skincare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIona Cosmetics and Skincare is a stable cash cow within Zeria Pharmaceutical Co., serving a loyal premium mineral-based skincare niche that generated approximately JPY 3.2 billion in revenue and ~12% operating margin in FY2024 (ending Mar 2025).\u003c\/p\u003e\n\u003cp\u003eGrowth is low but steady—market share ~6% in Japan premium mineral skincare (2024) —it prioritizes cost-efficiency, tight SKUs, and contributes predictable EBITDA to Zeria’s consumer healthcare segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue FY2024: JPY 3.2B\u003c\/li\u003e\n\u003cli\u003eOperating margin: ~12%\u003c\/li\u003e\n\u003cli\u003eJapan premium mineral skincare share: ~6% (2024)\u003c\/li\u003e\n\u003cli\u003eRole: predictable EBITDA, low reinvestment need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZeria’s ¥35–38bn cash cows fund ~18% of GI R\u0026amp;D with ¥9–10bn operating cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZeria’s cash cows (Hepalyse, chondroitin, zinc anti-ulcerants, WithOne laxatives, Iona skincare) generated ~¥35–38bn revenue in FY2024 with EBITDA margins 20–30% (Hepalyse ≈¥18–22bn EBITDA); combined operating cash flow ≈¥9–10bn, funding 18% of GI R\u0026amp;D in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Rev (¥bn)\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eOp CF (¥bn)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepalyse\u003c\/td\u003e\n\u003ctd\u003e~18–22\u003c\/td\u003e\n\u003ctd\u003e25–30%\u003c\/td\u003e\n\u003ctd\u003e~5–6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChondroitin\u003c\/td\u003e\n\u003ctd\u003e~6.5\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003ctd\u003e~2.9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZinc AU\u003c\/td\u003e\n\u003ctd\u003e~4.2\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003ctd\u003e~1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWithOne\u003c\/td\u003e\n\u003ctd\u003e~3.6\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003ctd\u003e~0.9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIona\u003c\/td\u003e\n\u003ctd\u003e~3.2\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003ctd\u003e~0.38\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eZeria Pharmaceutical Co. BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final Zeria Pharmaceutical Co. BCG Matrix you'll receive after purchase—no watermarks, no demo placeholders—just a fully formatted, analysis-ready report tailored for strategic decision-making and stakeholder presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748605669753,"sku":"zeria-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zeria-bcg-matrix.png?v=1772209780","url":"https:\/\/matrixbcg.com\/products\/zeria-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}